SEC Form 4 · accession 0001140361-16-048509
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
II Robert C. Goeltz
Officer — Chief Financial Officer
Period of report
Jan 21, 2016
Accepted (ET)
Jan 25, 2016 · 8:43 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $14.46 | Jan 21, 2016 | A | 80,000 | A | — | Jan 20, 2016 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1This option vests in 48 substantially equal monthly installments starting on January 1, 2016.
Remarks
Exhibit 24.1 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the reporting person on October 7, 2015)